Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00470977
Other study ID # Protocol: FVF4140S
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received May 4, 2007
Last updated October 24, 2012
Start date May 2007
Est. completion date December 2010

Study information

Verified date October 2012
Source Manhattan Eye, Ear & Throat Hospital
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of intravitreal injections of ranibizumab in the treatment of AMD variants and other choroidal neovascularization (CNV) related conditions (Coats' disease, idiopathic perifoveal telangiectasia, retinal angiomatous proliferation, polypoidal vasculopathy, pseudoxanthoma elasticum, pathological myopia, multi-focal choroiditis, rubeosis iridis) using the incidence and severity of adverse events.

Limited forms of treatment are available that limit the loss of visual acuity. However, the patients may not have any substantial improvement in acuity or function. Therefore there remains a significant unmet need for therapeutic options managing the neovascularization and its consequences.

Lucentis (ranibizumab) injection will be considered as an attempt to control the growth of the abnormal vessels because of evidence suggesting that angiogenic factors, such as vascular endothelial growth factor (VEGF), play a role in the pathogenesis of neovascular non-AMD conditions.

The rationale for the study design is as follows:

A 0.5 mg dose of Lucentis (ranibizumab), a commercially available preparation that is Food and Drug Administration (FDA) approved and labeled for intravitreal injection use for neovascular (wet) age-related macular degeneration will be used.

In AMD variants and other CNV related conditions, vascular endothelial growth factor (VEGF) plays a role in the pathogenesis as in neovascular AMD.

Intravitreal injection of ranibizumab delivers maximal concentration of the antibody fragment to the vitreous cavity with minimal systemic exposure. The dosing schedule, based on considerations of the half-life and the clinical response in patients with neovascularization suggests that a 1-month interval is optimal.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date December 2010
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

Subjects will be eligible if the following criteria are met:

1. Ability to provide written informed consent and comply with study assessments for the full duration of the study

2. Age > 18 years

3. Clinical diagnosis of the following conditions: Coats' disease, idiopathic perifoveal telangiectasia, retinal angiomatous proliferation, polypoidal vasculopathy, pseudoxanthoma elasticum, pathological myopia, multi-focal choroiditis, rubeosis iridis.

4. Visual acuity of 20/40 to 20/320 in the study eye on the ETDRS visual acuity chart.

5. Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from this study:

1. Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy is initiated

2. Participation in another simultaneous medical investigation or trial

3. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.

4. Patients who have undergone intraocular surgery within the last 2 months.

5. Patient participating in any other investigational drug study.

6. Use of an investigational drug or treatment related or unrelated to the patient's condition within 30 days prior to receipt of study medication (verteporfin, pegaptanib, or other AMD therapy in the study eye)

7. Patient treated with systemic anti-VEGF or pro-VEGF agents within 3 months before enrollment.

8. Previous treatment (in either eye) with intravitreal or intravenously administered Avastin (bevacizumab).

9. Inability to obtain photographs to document CNV (including difficulty with venous access).

10. Patient with a known adverse reaction to fluorescein dye.

11. Patient has a history of any medical condition which would preclude scheduled visits or completion of the study.

12. Patient has had insertion of scleral buckle in the study eye

13. Patient has received radiation treatment.

14. Aphakia or absence of the posterior capsule in the study eye. Previous violation of the posterior capsule in the study eye is also excluded unless as a result of yttrium aluminum garnet (YAG) posterior capsulotomy in association with posterior chamber lens implantation.

15. Pregnancy (positive pregnancy test) or lactation.

16. Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an intrauterine device (IUD), or contraceptive hormone implant or patch.

17. History of glaucoma filtering surgery in the study eye.

18. Concurrent use of more than two therapies for glaucoma.

19. Uncontrolled glaucoma in the study eye (defined as intraocular pressure > 30 mm Hg despite treatment with anti-glaucoma medication)

20. Inability to comply with study or follow-up procedure

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
ranibizumab injection (0.5 mg)
ranibizumab 10mg mg/ml. , 0.3ml/vial, 0.05 ml./injection intravitreally for 3months then prn for the next 21 months.

Locations

Country Name City State
United States Lenox Hill Hospital/Manhattan Eye Ear and Throat Institute New York New York
United States Lenox Hill Hospital/Manhattan Eye, Ear & Throat Institute New York New York

Sponsors (2)

Lead Sponsor Collaborator
Manhattan Eye, Ear & Throat Hospital Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability of intravitreal injections of ranibizumab in the treatment of non-AMD variants and other CNV related conditions 24 months Yes
Secondary Mean change in central retinal thickness as measured by OCT at month 12 compared to baseline 24 months Yes
Secondary Change in leakage area seen during fluorescein angiography at month 12 as compared with baseline 24 months Yes
Secondary Number of additional injections required following the initial 3 injections 24 months Yes
See also
  Status Clinical Trial Phase
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Active, not recruiting NCT01950741 - Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Phase 4
Completed NCT01469156 - Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy Phase 1/Phase 2
Recruiting NCT02597855 - Comparison of the Short-term Outcomes of Intravitreal Aflibercept Injection Between Two Subtypes of Polypoidal Choroidal Vasculopathy Using Indocyanine Green Angiography N/A
Completed NCT02495181 - Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy Phase 4
Active, not recruiting NCT02976194 - Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy Phase 4
Recruiting NCT01248117 - Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy Phase 1/Phase 2
Completed NCT01884597 - Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) Phase 1/Phase 2
Recruiting NCT04707027 - Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept N/A
Recruiting NCT02141308 - OCT in Rare Chorioretinal Diseases
Completed NCT01871376 - Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation Phase 4
Recruiting NCT00383812 - Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy N/A
Completed NCT00837330 - Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy Phase 1/Phase 2
Completed NCT05229237 - Conbercept for Polypoidal Choroidal Vasculopathy(START Study)
Not yet recruiting NCT04380974 - Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy Phase 4
Recruiting NCT02815176 - Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers N/A
Active, not recruiting NCT00344617 - Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy Phase 3
Recruiting NCT03929731 - Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)
Completed NCT01023295 - Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV) Phase 2
Completed NCT02821520 - Initial Versus Delayed PDT Combination With Conbercept in PCV Phase 4